Immunotherapy
By Laura Morgan
This article highlights the new therapies targeting a specific biomarker that have become available for patients with non–small-cell lung cancer in the past 3 years, significantly improving patient survival. Read More ›
By Dana Taylor
Lung cancer is divided into 2 main categories that require different therapies. Most of the new therapies are for the common type, but recently, immunotherapy has shown promise for this less common lung cancer type. Read More ›
Dr. Binder, of the University of California, San Diego, describes immunotherapy as the most recent advance in the treatment of endometrial cancer. Read More ›
By Mu Lin
Many side effects of immunotherapy can be effectively managed with early detection and intervention. It is important that patients with cancer and their caregivers know what symptoms to look for. Read More ›
On August 17, 2021, the FDA accelerated the
approval of Jemperli (dostarlimab-gxly; from
GlaxoSmithKline) injection, an immunotherapy and
a PD-1 inhibitor, for the treatment of all adults with
recurrent (coming back) or advanced mismatch
repair-deficient (dMMR) solid tumors, including
lung cancer, that progressed during or after systemic
therapy and for whom there are no satisfactory alternative treatment options. Read More ›
By Wayne Kuznar
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›
In this special issue focused on immunotherapy, we take a deep dive into this exciting type of treatment, highlighting the role of genetic testing and new developments in lung, skin, and bladder cancer in improving patient outcomes. Read More ›
Christie Bevington shares her story of how immunotherapy was the only treatment that helped stop her cancer progression and relieve her back pain caused by lung cancer. Read More ›
Tim Dorius, MD, explains the role of molecular profiling in relation to immunotherapy, and how oncologists can now look at the genetic makeup of a tumor to identify specific mutations or other biomarkers. Read More ›